[go: up one dir, main page]

AP2009004763A0 - Pyrazole derivatives as cytochrome P450 inhibitors - Google Patents

Pyrazole derivatives as cytochrome P450 inhibitors

Info

Publication number
AP2009004763A0
AP2009004763A0 AP2009004763A AP2009004763A AP2009004763A0 AP 2009004763 A0 AP2009004763 A0 AP 2009004763A0 AP 2009004763 A AP2009004763 A AP 2009004763A AP 2009004763 A AP2009004763 A AP 2009004763A AP 2009004763 A0 AP2009004763 A0 AP 2009004763A0
Authority
AP
ARIPO
Prior art keywords
cytochrome
inhibitors
pyrazole derivatives
pyrazole
derivatives
Prior art date
Application number
AP2009004763A
Other languages
English (en)
Inventor
Rongliang Chen
Simon Paul Planken
Scott Channing Sutton
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2009004763A0 publication Critical patent/AP2009004763A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AP2009004763A 2006-07-05 2007-06-25 Pyrazole derivatives as cytochrome P450 inhibitors AP2009004763A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80659606P 2006-07-05 2006-07-05
US91098807P 2007-04-10 2007-04-10
US94180807P 2007-06-04 2007-06-04
PCT/IB2007/001878 WO2008004096A1 (en) 2006-07-05 2007-06-25 Pyrazole derivatives as cytochrome p450 inhibitors

Publications (1)

Publication Number Publication Date
AP2009004763A0 true AP2009004763A0 (en) 2009-02-28

Family

ID=38515807

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2009004763A AP2009004763A0 (en) 2006-07-05 2007-06-25 Pyrazole derivatives as cytochrome P450 inhibitors

Country Status (24)

Country Link
US (1) US7919488B2 (no)
EP (1) EP2046774A1 (no)
KR (1) KR20090034958A (no)
CN (1) CN101511812A (no)
AP (1) AP2009004763A0 (no)
AR (1) AR062154A1 (no)
AU (1) AU2007270814B2 (no)
CA (1) CA2660031A1 (no)
CO (1) CO6150178A2 (no)
CR (1) CR10573A (no)
EA (1) EA200900135A1 (no)
GT (1) GT200700053A (no)
IL (1) IL196490A0 (no)
MA (1) MA30629B1 (no)
MX (1) MX2009000482A (no)
NO (1) NO20090346L (no)
NZ (1) NZ574207A (no)
PE (1) PE20080998A1 (no)
RS (1) RS20090036A (no)
TN (1) TN2009000033A1 (no)
TW (1) TWI334867B (no)
UY (1) UY30460A1 (no)
WO (1) WO2008004096A1 (no)
ZA (1) ZA200900478B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101534824A (zh) * 2006-11-17 2009-09-16 艾博特公司 作为化学活素受体拮抗剂的氨基吡咯烷
EA200901240A1 (ru) * 2007-03-13 2010-02-26 Эрет Терэпьютикс, Инк. Соединения 4-пиперидинилмочевины (варианты), фармацевтическая композиция на их основе (варианты) и способ лечения заболевания, опосредованного растворимой эпоксидгидролазой, посредством названных соединений (варианты)
EP2257536A4 (en) 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
EP2268611A2 (en) 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
UY33476A (es) 2010-06-30 2012-02-29 Ironwood Pharmaceuticals Inc Estimuladores de sgc
RU2016101964A (ru) 2010-11-09 2018-11-21 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ sGC
EP3112363A1 (en) 2011-12-27 2017-01-04 Ironwood Pharmaceuticals, Inc. 2-[1-[(2-fluorophenyl)methyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl]-pyrimidine derivatives and related compounds as soluble guanylate cyclase (sgc) stimulators for the treatment of pulmonary hypertension
CN104540813A (zh) * 2012-06-27 2015-04-22 默沙东公司 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法
WO2014000178A1 (en) * 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2014194519A1 (en) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug
WO2015070366A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2015070367A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2020163689A1 (en) * 2019-02-08 2020-08-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 20-hete formation inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0024795D0 (en) * 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
MXPA03008089A (es) * 2001-04-05 2004-01-22 Torrent Pharmaceuticals Ltd Compuestos heterociclicos para complicaciones relacionadas con el envejecimiento y vasculares diabeticas.
US7008953B2 (en) * 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7662844B2 (en) * 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
WO2007034312A2 (en) * 2005-09-23 2007-03-29 Pfizer Products Inc. Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)

Also Published As

Publication number Publication date
TN2009000033A1 (fr) 2010-08-19
NZ574207A (en) 2010-10-29
MX2009000482A (es) 2009-01-27
AR062154A1 (es) 2008-10-22
CN101511812A (zh) 2009-08-19
IL196490A0 (en) 2011-07-31
ZA200900478B (en) 2010-04-28
US7919488B2 (en) 2011-04-05
PE20080998A1 (es) 2008-08-15
CR10573A (es) 2009-02-12
TWI334867B (en) 2010-12-21
CO6150178A2 (es) 2010-04-20
KR20090034958A (ko) 2009-04-08
EP2046774A1 (en) 2009-04-15
AU2007270814A1 (en) 2008-01-10
NO20090346L (no) 2009-02-19
WO2008004096A1 (en) 2008-01-10
RS20090036A (sr) 2010-06-30
EA200900135A1 (ru) 2009-06-30
UY30460A1 (es) 2008-02-29
MA30629B1 (fr) 2009-08-03
AU2007270814B2 (en) 2011-07-14
CA2660031A1 (en) 2008-01-10
US20080021011A1 (en) 2008-01-24
TW200811159A (en) 2008-03-01
GT200700053A (es) 2009-08-03

Similar Documents

Publication Publication Date Title
AP2009004763A0 (en) Pyrazole derivatives as cytochrome P450 inhibitors
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
EP2057158B8 (en) Triazole derivatives as kinase inhibitors
IL193413A0 (en) Pyrrolidine derivatives as erk inhibitors
IL192603A0 (en) Thieno-pyridine derivatives as mek inhibitors
ZA200810673B (en) 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof
EP2078001B8 (en) Diazepane-acetamide derivatives as selective 11 -hsd1 inhibitors
IL194367A0 (en) Dihydropyrazolopyrimidinone derivatives
IL196543A0 (en) Pyridizinone derivatives
IL193641A0 (en) Spiroindolinone derivatives
IL195013A0 (en) Pyridopyrimidinone derivatives
IL198319A0 (en) Spiroindolinone derivatives
IL195422A0 (en) 2-pyrazinecarboxamide derivatives
EP2046333A4 (en) THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE
EP2015745A4 (en) MACROCYCLIC KINASE INHIBITORS
IL197103A0 (en) Compositions for inhibiting cytochrome p450
IL198059A0 (en) 2-aminocarbonyl-pyridine derivatives
IL196364A0 (en) Aminoindazolylurea derivatives
IL193211A0 (en) Indazole-heteroaryl derivatives
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
EP2084135A4 (en) PYRAZOLES
IL205602A0 (en) Pyrazole derivatives as 5-lo inhibitors
ZA200906423B (en) Pyrazolone derivatives as PDE4 inhibitors
IL197239A0 (en) Phenyloxyaniline derivatives